Early trial tests new combo for Tough-to-Treat head & neck cancers
NCT ID NCT03381183
Summary
This early-stage study tested the safety of combining two immunotherapy drugs, IRX-2 and durvalumab, for patients with incurable head and neck cancer. The main goal was to find the highest dose patients could tolerate without severe side effects and to see if the treatment increased immune cell activity inside the tumors. It involved 19 adults whose cancer had returned or spread and could not be cured with surgery or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.